Retrosynthesis of the First Non-Steroidal Treatment of HAE

SYNTHIA Retrosynthesis Software Berotralstat Synthesis

SYNTHIA™ Retrosynthesis Software is a decision support platform that helps synthetic chemists and process chemists alike tackle structurally diverse chemical targets, both previously reported in the literature or completely unknown (like e.g., novel drug candidates or recently isolated natural products). Using one of our default search configurations, SYNTHIA™ designed an efficient, convergent, chiral synthesis of an oral plasma kallikrein inhibitor, berotralstat, starting with moderately priced commercial compounds. The berotralstat retrosynthesis is important because this novel drug was recently approved as the first non-steroidal treatment of hereditary angioedema (HAE). SYNTHIA™ Retrosynthesis Software can spark creativity in your synthetic planning by quickly designing routes for target molecules based on your requirements. Sign up for a live demo, contact us here.

Reach out to us

Quickly go from imagining what‘s possible to testing what‘s probable with a license that fits your needs.